Evidence map›Paper›PMID 25035660›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2014

Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer.

Jian Wang, Xi-Qiao Zhou, Jing-Ying Li, Jian-Feng Cheng, Xiao-Ning Zeng, Xiao Li, Ping Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jian Wang1 Department of Oncology, 2 Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China ; 3 Department of Oncology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330000, China ; 4 Gastroenterology, Department of Internal Medicine, Carolinas Medical Center, University of North Carolina Charlotte Campus, 1000 Blythe Blvd, Charlotte, NC 28203, USA ; 5 Department of Respiratory Medicine, 6 Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Xi-Qiao Zhou1 Department of Oncology, 2 Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China ; 3 Department of Oncology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330000, China ; 4 Gastroenterology, Department of Internal Medicine, Carolinas Medical Center, University of North Carolina Charlotte Campus, 1000 Blythe Blvd, Charlotte, NC 28203, USA ; 5 Department of Respiratory Medicine, 6 Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Jing-Ying Li1 Department of Oncology, 2 Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China ; 3 Department of Oncology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330000, China ; 4 Gastroenterology, Department of Internal Medicine, Carolinas Medical Center, University of North Carolina Charlotte Campus, 1000 Blythe Blvd, Charlotte, NC 28203, USA ; 5 Department of Respiratory Medicine, 6 Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Jian-Feng Cheng1 Department of Oncology, 2 Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China ; 3 Department of Oncology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330000, China ; 4 Gastroenterology, Department of Internal Medicine, Carolinas Medical Center, University of North Carolina Charlotte Campus, 1000 Blythe Blvd, Charlotte, NC 28203, USA ; 5 Department of Respiratory Medicine, 6 Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Xiao-Ning Zeng1 Department of Oncology, 2 Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China ; 3 Department of Oncology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330000, China ; 4 Gastroenterology, Department of Internal Medicine, Carolinas Medical Center, University of North Carolina Charlotte Campus, 1000 Blythe Blvd, Charlotte, NC 28203, USA ; 5 Department of Respiratory Medicine, 6 Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Xiao Li1 Department of Oncology, 2 Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China ; 3 Department of Oncology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330000, China ; 4 Gastroenterology, Department of Internal Medicine, Carolinas Medical Center, University of North Carolina Charlotte Campus, 1000 Blythe Blvd, Charlotte, NC 28203, USA ; 5 Department of Respiratory Medicine, 6 Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Ping Liu1 Department of Oncology, 2 Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China ; 3 Department of Oncology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330000, China ; 4 Gastroenterology, Department of Internal Medicine, Carolinas Medical Center, University of North Carolina Charlotte Campus, 1000 Blythe Blvd, Charlotte, NC 28203, USA ; 5 Department of Respiratory Medicine, 6 Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study explored the correlation between the expression of excision repair cross-complementation group 1 (ERCC1) and the prognosis of gastric cancer patients.

methodsFrom January 2005 to December 2008, 605 patients who underwent radical surgery in The First Affiliated Hospital of Nanjing Medical University were enrolled. We conducted the follow-up every 6 months and its contents included a comprehensive medical history, tumor markers and abdominal ultrasound or CT and other imaging findings. Deadline was April 30, 2013 and follow-up time between 51 to 91 months. Survival time is calculated from the date of diagnosis to death or last follow-up date. Immunohistochemistry (IHC) was used to assess the expression of ERCC1 in resected samples. The relationship between ERCC1 expression and survival of patients was investigated. The comparison of count data were analyzed by Chi-square test. Median survival time (MST) and the 5-year survival rate were calculated by life table analysis. The Kaplan-Meier curves were used for survival analysis.

resultsERCC1 expression was positive in 412 patients (68.1%). There is no significant difference between ERCC1-positive group and ERCC1-negative group in terms of the MST and 5-year survival rate (P=0.455). The MST and 5-year survival rate have no significant difference (P=0.162) between group with chemotherapy and group with no chemotherapy in patients with ERCC1-positive expression. However, the MST and 5-year survival rate in patients with ERCC1-negative expression benefited more from with chemotherapy (P=0.019). The ERCC1-positive patients survived longer than those ERCC1-negative patients (P=0.183) in subgroup with no adjuvant chemotherapy. In the subgroup analysis, ERCC1 expression had no significant relationship with overall survival in patients with stage II or III gastric cancer (P>0.05).

conclusionsERCC1 might be a good prognostic factor for the patients of gastric cancer after radical resection. Patients with ERCC1-negative expression could benefit more from adjuvant chemotherapy.

Indexed as

excision repair cross-complementation group 1 (ERCC1)Gastric cancerplatinum drugsprognosis

Identifiers

PMID25035660
PMCPMC4076725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.